Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.51 |
| ▸ | TUBB | P07437 | 2/20 | 0.51 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.51 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.51 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.51 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.51 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.51 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.51 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.51 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.51 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.51 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.51 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.51 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.51 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30120616 | 1.00 | KDM4E (0.56) | KDM4ERECQLPARP14TUBB4ATUBB | |
| SCHEMBL6930954 | 0.88 | KDM4E (0.63) | KDM4ERECQLPARP14SMN1; SMN2NPC1 | |
| SCHEMBL30120759 | 0.88 | KDM4E (0.63) | KDM4ERECQLPARP14SMN1; SMN2NPC1 | |
| SCHEMBL17298077 | 0.86 | TNKS2 (0.64) | KDM4EPARP14TUBB4ATUBBTUBA3C | |
| SCHEMBL31332096 | 0.86 | PARP14 (0.56) | KDM4EPARP14TUBB4ATUBBTUBA3C | |
| SCHEMBL9555910 | 0.84 | PARP14 (0.55) | KDM4EPARP14TUBB4ATUBBTUBA3C | |
| SCHEMBL30259528 | 0.83 | TUBB4A (0.68) | KDM4ERECQLTUBB4ATUBBTUBA3C | |
| SCHEMBL6928482 | 0.83 | TUBB4A (0.68) | KDM4ERECQLTUBB4ATUBBTUBA3C | |
| SCHEMBL19104691 | 0.82 | PARP14 (0.53) | KDM4EPARP14TUBB4ATUBBTUBA3C | |
| SCHEMBL31332346 | 0.82 | PARP14 (0.53) | KDM4EPARP14TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| CN-115010671-B | One-step synthesis method of 2-substituted quinazolinone | 江苏大学 | 2023-10-10 | — | — | CN | disclosed |
| EP-4212515-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-4212515-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230150978-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO PHARMA (FR) | 2023-05-18 | — | — | US | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| EP-4126847-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO Pharma (FR) | 2023-02-08 | — | — | EP | disclosed |
| EP-3728207-B1 | QUINAZOLINONES AS PARP14 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-3728207-B1 | QUINAZOLINONES AS PARP14 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| CN-103755647-B | C2 bit derivant of 4 (3H)-quinazolinones and its production and use | CAPITAL NORMAL UNIV. (CN) | 2015-12-09 | — | — | CN | disclosed |
| CN-103755647-A | C2-bit derivative of 4(3H)-quinazolinone and preparation method and application thereof | UNIV CAPITAL NORMAL | 2014-04-30 | — | — | CN | disclosed |
| WO-2011012622-A1 | BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-02-03 | — | — | WO | disclosed |
| US-5387585-A | Treating epilepsy, anxiety, sleep disorders, schizophrnia, senile dementia | HOFFMANN-LA ROCHE INC. (US) | 1995-02-07 | — | — | US | disclosed |
| US-5187167-A | Antitumor agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-16 | — | — | US | disclosed |
| EP-0519307-A2 | Tetracyclic Imidazodiazepines | F. HOFFMANN-LA ROCHE AG (CH) | 1992-12-23 | — | — | EP | disclosed |
| US-5081124-A | Amino acid and polyamino acid derivatives, inhibitors of thymidylate synthetase | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-01-14 | — | — | US | disclosed |
| EP-0239362-B1 | ANTI-TUMOR AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-12-04 | — | — | EP | disclosed |
| US-4992550-A | Thymidylate synthetase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-02-12 | — | — | US | disclosed |
| EP-0239362-A2 | Anti-tumor agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150978-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | NQO2, NQO1, NDUFV2 | KDM4E 1813/4885RECQL 90/4885PARP14 571/4885 |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | IDUA, MAN2B1, GBA1 | KDM4E 3566/4885RECQL 212/4885PARP14 3715/4885 |
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | KDM4E 383/4885RECQL 538/4885PARP14 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.